{"id":102571,"date":"2025-03-20T11:24:51","date_gmt":"2025-03-20T11:24:51","guid":{"rendered":"https:\/\/alertindianews.in\/?p=102571"},"modified":"2025-03-20T11:24:51","modified_gmt":"2025-03-20T11:24:51","slug":"once-a-week-shot-weight-loss-drug-mounjaro-launched-in-india-by-eli-lilly","status":"publish","type":"post","link":"https:\/\/alertindianews.in\/?p=102571","title":{"rendered":"&#8216;Once-A-Week Shot&#8217; Weight-Loss Drug Mounjaro Launched In India By Eli Lilly"},"content":{"rendered":"<p>Eli Lilly and Company (India) on Thursday said it has launched a first-of-its-kind medication for obesity and type 2 diabetes in the country after obtaining approval from the Central Drugs Standard Control Organisation (CDSCO).<\/p>\n<p>The company said it has introduced Mounjaro in a single-dose vial presentation following the marketing authorisation from the CDSCO.<\/p>\n<p>It is a first-of-its-kind treatment for obesity, overweight, and type 2 diabetes that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors.<\/p>\n<p>Mounjaro is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg\/m2 or greater (obesity) or 27 kg\/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition.<\/p>\n<p>It is also indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.<\/p>\n<p>&#8220;The dual burden of obesity and type 2 diabetes is rapidly emerging as a major public health challenge in India. Lilly is committed to collaborating with the government and industry to promote awareness and improve the prevention and management of these diseases,&#8221; Eli Lilly India President and General Manager Winselow Tucker said.<\/p>\n<p>The company&#8217;s mission is to make life better for people living with obesity and diabetes in India, he added.<\/p>\n<p>India has about 101 million people living with diabetes and nearly half of these in the adult patients category are being inadequately treated with suboptimal glycemic control.<\/p>\n<p>Obesity, a chronic relapsing disease, is a major risk factor for diabetes and is linked to over 200 health complications, including hypertension, dyslipidemia, coronary heart disease, and obstructive sleep apnea.<\/p>\n<p>As of 2023, adult obesity prevalence in India stood at around 6.5 per cent, affecting nearly 100 million people.<\/p>\n<p>Once-a-weekly, prescription-based medicine, Mounjaro is a single molecule that selectively binds to and activates both GIP and GLP-1 receptors, which are natural incretin hormones.<\/p>\n<p><i>(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)<\/i><\/p>\n<p>\u200bEli Lilly and Company (India) on Thursday said it has launched a first-of-its-kind medication for obesity and type 2 diabetes in the country after obtaining approval from the Central Drugs Standard Control Organisation (CDSCO).\u00a0\u00a0<\/p>","protected":false},"excerpt":{"rendered":"<p>Eli Lilly and Company (India) on Thursday said it has launched a first-of-its-kind medication for obesity and type<\/p>\n","protected":false},"author":0,"featured_media":102572,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-102571","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/alertindianews.in\/index.php?rest_route=\/wp\/v2\/posts\/102571","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alertindianews.in\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alertindianews.in\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/alertindianews.in\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=102571"}],"version-history":[{"count":0,"href":"https:\/\/alertindianews.in\/index.php?rest_route=\/wp\/v2\/posts\/102571\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alertindianews.in\/index.php?rest_route=\/wp\/v2\/media\/102572"}],"wp:attachment":[{"href":"https:\/\/alertindianews.in\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=102571"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alertindianews.in\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=102571"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alertindianews.in\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=102571"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}<!-- This website is optimized by Airlift. Learn more: https://airlift.net. Template:. Learn more: https://airlift.net. Template: 6a4b5deb190636d5f833cb99. Config Timestamp: 2026-07-06 07:48:59 UTC, Cached Timestamp: 2026-07-29 08:03:39 UTC, Optimization Time: 7.87ms -->